Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online April 27, 2007
Diabetes Care 30:1906-1908, 2007
DOI: 10.2337/dc07-0189
© 2007 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0189v1
30/7/1906    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morínigo, R.
Right arrow Articles by Vidal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morínigo, R.
Right arrow Articles by Vidal, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cardiovascular and Metabolic Risk
Brief Report

Insulin Resistance, Inflammation, and the Metabolic Syndrome Following Roux-en-Y Gastric Bypass Surgery in Severely Obese Subjects

Rosa Morínigo, MD1, Roser Casamitjana, PHD2, Salvadora Delgado, MD, PHD1, Antonio Lacy, MD, PHD1, Ramon Deulofeu, PHD2, Ignacio Conget, MD, PHD3, Silvia Barceló-Batllori, PHD4, Ramon Gomis, MD, PHD3,4 and Josep Vidal, MD, PHD1

1 Obesity Unit, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic Universitari, Barcelona, Spain
2 Biological Diagnostics, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic Universitari, Barcelona, Spain
3 Diabetes Unit, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic Universitari, Barcelona, Spain
4 Laboratory of Experimental Diabetes, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic Universitari, Barcelona, Spain

Address correspondence and reprint requests to Dr. Josep Vidal, Obesity Unit, Hospital Clínic Universitari, Villarroel 170, 08036 Barcelona, Spain. E-mail: jovidal{at}clinic.ub.es

Abbreviations: CRP, C-reactive protein • FPG, fasting plasma glucose • HOMA-IR, homeostasis model assessment of insulin resistance • RYGBP, Roux-en-Y gastric bypass


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 
Several studies have demonstrated the benefits of massive weight reduction following Roux-en-Y gastric bypass (RYGBP) on the metabolic syndrome (1–3). However, the time course of the effects of RYGBP on the metabolic syndrome components and its potential underlying mechanisms has not been reported. In recent years, it has been proposed that low-grade chronic inflammation is a critical factor underlying the metabolic syndrome (4–6). Alternatively, it has been proposed that the metabolic syndrome would be better explained by a combination of factors including but not limited to low-grade systemic inflammation (7). The aim of our study was to evaluate the time course of metabolic syndrome components, insulin sensitivity and inflammatory markers, following laparoscopic RYGBP in severely obese subjects. To discriminate the effects of modest (10% of initial body weight) versus massive weight loss on the evaluated parameters, we assessed subjects at 6 and 52 weeks after surgery.


   RESEARCH DESIGN AND METHODS—
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
RESULTS--
 CONCLUSIONS--
 References
 
A total of 36 Caucasian, severely obese subjects about to undergo RYGBP surgery (8) were evaluated (Table 1). Twenty normal-weight healthy volunteers, matched for sex and age with the obese subjects, served as controls (Table 1). The study was approved by the hospital ethics committee. Written informed consent was obtained from all participants. The 36 obese, operated subjects were evaluated within 8 weeks before RYGBP and again at 6 and 52 weeks after RYGBP. Control subjects were evaluated on a single occasion.


View this table:
[in this window]
[in a new window]

  		Table 1— Clinical characteristics, insulin sensitivity, and inflammatory markers in severely obese and normal-weight control subjects at the three study time points

 
The diagnosis of the metabolic syndrome was based on the revised Adult Treatment Panel III criteria (9). Anthropometrical and blood pressure measurements were performed as previously described (10). Venous blood was collected after an overnight fast. Plasma glucose, total cholesterol, HDL cholesterol, triglyceride levels, insulin, adiponectin, and insulin sensitivity (homeostasis model assessment of insulin resistance [HOMA-IR]) were assessed as previously described (10). The leukocyte count was measured using an Advia 2400 analyzer (Bayer Diagnostics, Tarrytown, NY). High-sensitive C-reactive protein (CRP) was determined using an inmunonefelometric method (Boehring Nephelometer analyzer; Dade Boehring, Marburg, Germany). Soluble tumor necrosis factor-{alpha} receptors 1 (p55/p60) and 2 (p75/p80) (HyCult Biotechnology, Uden, Netherlands) and resistin (Linco Research, St. Charles, MO) were measured by an enzyme-linked immunosorbent assay.

All data are expressed as means ± SEM. Statistical analyses were carried out using SPSS software (version 11.5; SPSS, Chicago, IL). {chi}2 and nonparametric test (Mann-Whitney U, Friedman, or Kruskall-Wallis) were used for comparisons between groups. Correlations were analyzed using Spearman rank correlation analysis or partial correlation analysis. Statistical significance was set at P < 0.05.


   RESULTS—
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
CONCLUSIONS--
 References
 
The time course of the prevalence of the metabolic syndrome and its individual components is shown in Table 1.

Insulin sensitivity and the metabolic syndrome
Before surgery, a significant correlation was found between HOMA-IR and the number of metabolic syndrome components (r = 0.570, P < 0.005). HOMA-IR significantly correlated with fasting plasma glucose (FPG) (r = 0.659, P < 0.001) and tended to correlate with systolic blood pressure (P = 0.071) and waist circumference (P = 0.074), albeit it did not reach statistical significance. HOMA-IR significantly declined following RYGBP (Table 1). At 6 weeks, HOMA-IR significantly correlated with FPG (r = 0.589, P < 0.005), triglycerides (r = 0.367, P < 0.05), and HDL cholesterol (r = –0.339, P < 0.05). At 52 weeks, HOMA-IR significantly correlated with the number of metabolic syndrome components (r = 0.366, P < 0.05) and with FPG (r = 0.394, P < 0.05). The correlations between HOMA-IR and components of the metabolic syndrome remained significant even after controlling for the different inflammatory parameters.

Inflammatory markers and the metabolic syndrome
Before surgery, no significant correlation was found between inflammatory markers and the individual metabolic syndrome components, the number of metabolic syndrome components present in one particular individual, or HOMA-IR. At 6 weeks, changes in some of the inflammatory markers were observed (Table 1). The leukocyte count was the only showing significant correlations with metabolic syndrome components (waist circumference and systolic blood pressure), but these associations lost significance when HOMA-IR was considered. At 52 weeks, we observed a significant decline in the evaluated proinflammatory markers (except for resistin) and an increase in plasma adiponectin relative to baseline. Again, we did not find a significant correlation between the number of metabolic syndrome components and the inflammatory parameters. However, the leukocyte count significantly correlated with systolic and diastolic blood pressure (respectively, r = 0.384, P < 0.05; and r = 0.387, P < 0.05) and triglycerides (r = 0.393, P < 0.05). Adiponectin significantly correlated with the waist circumference (r = –0.365, P < 0.05), diastolic blood pressure (r = –0.387, P = 0.05), triglycerides (r = –0.345, P < 0.05), and HDL cholesterol (r = 0.355, P < 0.05). High-sensitivity CRP significantly correlated with FPG (r = 0.34, P < 0.05). These correlations were barely affected when HOMA-IR was considered. Noteworthy, at 52 weeks after surgery most inflammatory markers remained altered when operated subjects were compared with the normal-weight cohort (Table 1).


   CONCLUSIONS—
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
References
 
Marked reductions in the prevalence of the metabolic syndrome have been observed after RYGBP at ≥1 year of follow up (1–3). Noteworthy, our data show that the improvement in the metabolic syndrome following RYGBP occurs shortly after the surgical procedure, at a time when the attained weight loss is still modest. This is consistent with reports showing an early amelioration of altered glucose homeostasis (11) and blood pressure (12) following this type of surgical technique.

It has been proposed that systemic low-grade inflammation is critical for the appearance of the metabolic sydrome and that an improvement in the inflammatory process is important for the beneficial effects of weight loss (4–6,13). However, our data would suggest a different scenario, at least in severe obesity. Our results are supported by recent findings that increased CRP levels are found in severely obese subjects irrespective of the presence of nonalcoholic steatohepatitis or the metabolic syndrome (14). Likewise, several studies have reported either no change or no association between inflammatory markers and changes in metabolic parameters at short term after RYGBP (15–18). Importantly, our data does not preclude a role of the inflammatory process in the improvement of the metabolic syndrome at longer follow-up. At 1 year after RYGBP, upon massive weight loss, our data and those from others demonstrate that changes in the inflammatory process may help to explain changes in the metabolic syndrome. A significant correlation between CRP plasma concentration (19) or adiponectin (17) and metabolic variables has previously been reported at 6 and 12 months after RYGBP.

The data from the current study suggest that the early changes in the metabolic syndrome following RYGBP are better explained by changes in insulin sensitivity. An early improvement in insulin sensitivity following RYGBP has previously been described (11,20). Interestingly, Petersen et al. (21) reported mechanistic studies on the changes of glucose homeostasis in type 2 diabetic subjects following a dietary intervention resulting in a weight loss similar to the one presented in our cohort at 6 weeks after surgery. The normalization of glucose homeostasis was associated with a marked improvement in whole-body insulin sensitivity, hepatic triglyceride content, and hepatic insulin sensitivity but with no changes in circulating levels of inflammatory markers.

We acknowledge our study has several limitations. The small sample size may not allow definite conclusions to be drawn. Second, the inflammatory process involves a complex interplay of inflammatory mediators (5,6), and we only measured a subset of these markers. Thus, further studies with a more comprehensive evaluation are needed to better understand the contribution of the inflammatory process in the changes in obesity-associated metabolic disturbances following RYGBP.

In summary, our data confirm previous reports on the inflammatory state associated with obesity. Moreover, our data support the view that obesity is an important contributor to the elevation of plasma concentration of inflammatory markers. Finally, we suggest that at short term after RYGBP, the changes in the metabolic syndrome components are better accounted for regarding improved insulin sensitivity than regarding decreased low-grade inflammation. Unraveling the mechanisms responsible for the metabolic disturbances associated with obesity may provide new targets to reduce the burden of obesity epidemics.


   Acknowledgments
 
This work was supported by grants from the Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III (PI060157 and REDIMET RD06/0,015), Madrid, Spain.


   Footnotes
 
Published ahead of print at http://care.diabetesjournals.org on 27 April 2007. DOI: 10.2337/dc07-0189.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Received for publication January 30, 2007. Accepted for publication April 18, 2007.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 

  1. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR: Effects of obesity surgery on the metabolic syndrome. Arch Surg 139:1088–1092, 2004[Abstract/Free Full Text]
  2. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, Eid GM, Ramanathan R, Taylor DS, Schauer PR: Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242:610–617, 2005[Medline]
  3. Madan AK, Orth W, Ternovits CA, Tichansky DS: Metabolic syndrome: yet another co-morbidity gastric bypass helps cure. Surg Obes Relat Dis 2:48–51, 2006[Medline]
  4. Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 444:881–886, 2006[Medline]
  5. Hotamisligil GS: Inflammation and metabolic disorders. Nature 444:860–867, 2006[Medline]
  6. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772–783, 2006[Medline]
  7. Hanley AJG, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM: Metabolic and inflammation variable clusters and prediction of type 2 diabetes. Diabetes 53:1773–1781, 2004[Abstract/Free Full Text]
  8. Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, Delgado S, Casamitjana R, Vidal J: Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91:1735–1740, 2006[Abstract/Free Full Text]
  9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 25:2735–2752, 2005
  10. Vidal J, Morinigo R, Codoceo VH, Casamitjana R, Pellitero S, Gomis R: The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. Int J Obes 29:668–674, 2005[Medline]
  11. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E: The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242, 2004[Medline]
  12. Czupryniak L, Strzelczyk J, Pawlowski M, Loba J: Circadian blood pressure variation in morbidly obese hypertensive patients undergoing gastric bypass surgery. Am J Hypertens 18:446–451, 2005[Medline]
  13. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, Stich V, Cancello R, Langin D: Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18:1657–1669, 2004[Abstract/Free Full Text]
  14. Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A, Amor IB, Staccini-Myx A, Huet PM, Gugenheim J, Sadoul JL, Le Marchand-Brustel Y, Tran A, Gual P: The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol 101:1824–1833, 2006[Medline]
  15. Molina A, Vendrell J, Gutierrez C, Simon I, Masdevall C, Soler J, Gomez JM: Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 13:615–621, 2003[Medline]
  16. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12:962–971, 2004[Medline]
  17. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, Van Loan MD, Ali MR, Wolfe BM, Havel PJ: Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 49:2552–2558, 2006[Medline]
  18. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54:2277–2286, 2005[Abstract/Free Full Text]
  19. Gletsu N, Lin E, Khaitan L, Lynch SA, Ramshaw B, Raziano R, Torres WE, Ziegler TR, Papanicolaou DA, Smith CD: Changes in C-reactive protein predict insulin sensitivity in severely obese individuals after weight loss surgery. J Gastrointest Surg 9:1119–1126, 2005[Medline]
  20. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS: Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 15:474–481, 2005[Medline]
  21. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608, 2005[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0189v1
30/7/1906    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morínigo, R.
Right arrow Articles by Vidal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morínigo, R.
Right arrow Articles by Vidal, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum